Abstract 76P
Background
Colorectal cancer (CRC) is the third cause of cancer-related death worldwide. Surgery is the primary treatment followed by radiotherapy and/or chemotherapy which have toxic side effects and can be ineffective. 2D cell cultures and animal models have been used for CRC drug development. Still, they cannot recapitulate the human anatomy or physiology or predict drug efficacy, resistance and toxicity. Patient-derived organoids (PDO) are three-dimensional in vitro stem cell cultures that recapitulate the organs' cell lineage, functions and tumour heterogeneity retaining patients’ tumour antigens and faithfully predicting treatment response. Since PDOs lack the immune microenvironment needed to better predict patients' responses and resistance, we optimised an in vitro CRC organoids and immune cell co-culture protocol to rapidly and efficiently assess CD3- T cell interactions, activation and capacity to recognise and kill tumour organoids using bioengineered T cell engaging bispecific molecules.
Methods
We co-cultured CRC organoids, non-autologous stimulated CD3-T cells in suspension with T cell engager molecules HER2 and EGFR. At the end of each co-culture dose-response assay we assessed organoid viability, CD3-CD4-CD8 T cell viability, activation and killing by time-lapse live cell imaging, flow cytometry and ELISA.
Results
As HER2 and EGFR T cell engager doses were increased, the viability of the organoids substantially dropped. Moreover, CD4+CD25+CD69+ and CD8+CD25+CD69+ T cell populations were detected by flow cytometry in the presence of both T cell engagers' molecules but not in the controls. Finally, higher levels of Interferon-gamma cytokine were observed in the supernatant of co-cultured organoids with HER2 and EGFR molecules compared to the controls.
Conclusions
We have recreated the complex tumour cells and immune microenvironment interaction to successfully profile the efficacy, activity and crosstalk between HER2 and EGFR immune engager compounds, tumour organoids and immune cell subsets across a range of target organoid genotypes and a range of immune cell donors, aiming to replicate patients’ response and prioritise suitable immunotherapy candidates without the need for murine models.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Prof. Andrew Beggs Group - The University of Birmingham and AstraZeneca UK Limited.
Funding
AstraZeneca UK Limited.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4P - Predicting triple-negative breast cancer molecular subtype from hematoxylin and eosin using deep neural networks
Presenter: Nicola Occelli
Session: Cocktail & Poster Display session
Resources:
Abstract
5P - Onconaut: A precision medicine platform for oncology therapies
Presenter: Altuna Akalin
Session: Cocktail & Poster Display session
Resources:
Abstract
6P - Diagnostic accuracy of artificial intelligence in classifying HER2 status in breast cancer immunohistochemistry slides: A systematic review and meta-analysis
Presenter: Daniel Arruda Navarro Albuquerque
Session: Cocktail & Poster Display session
Resources:
Abstract
8P - Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers
Presenter: Sofia Merajver
Session: Cocktail & Poster Display session
Resources:
Abstract
9P - Circulating tumor cells and circulating tumor DNA detection in colorectal cancer stage III patients receiving three or six months of adjuvant treatment
Presenter: Asimina Koulouridi
Session: Cocktail & Poster Display session
Resources:
Abstract
10P - Novel theranostic agents in non-metastatic Egyptian breast cancer patients: miR-96, miR-1275, miR-4317 and miR-744
Presenter: Ahmed Mokhtar
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - A prospective study to evaluate the prognostic implications and molecular mechanism of SLC40A1 gene in primary acute myeloid leukemia
Presenter: Harsh Goel
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Prognostic value of PD-L1 expression and neutrophil-to-lymphocyte ratio to neoadjuvant chemo-immunotherapy in muscle-invasive urothelial carcinoma patients from the AURA trial
Presenter: Jeremy Blanc
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - Methylation of BRCA1 and RAD51C promoters determined by droplet digital PCR predicts homologous repair deficiency in patients with high-grade serous ovarian cancer: Results of the BOVARY-pilot study in paired FFPE and plasma samples and the ICL ovarian cohort
Presenter: Cassandra Michel
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - SLFN11 detection in patients with small cell lung cancer treated with lurbinectedin: A retrospective translational analysis
Presenter: Daniela Scattolin
Session: Cocktail & Poster Display session
Resources:
Abstract